

GNIPST BULLETIN 2024

(Pharmacy)



VOLUME-1, ISSUE- 2



GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

1

Message from Director
and Principal

2

Latest News/ Research
News

3

Campus News

4

Games



MESSAGE FROM HONORABLE DIRECTOR

I extend my heartfelt greetings to you all. At Guru Nanak Institute of Pharmaceutical Science and Technology, we are committed to fostering an environment of academic excellence, innovation, and holistic development.

Our institution is dedicated in pursuit of Pharmaceutical Sciences. We believe in nurturing inquisitive minds, encouraging critical thinking, and developing skills of our beloved students. As we continue to grow and evolve, we remain steadfast in our mission to provide quality education and promote research and innovation. In this Independence Month, we also celebrate the spirit of freedom and innovation that drives our nation forward. We wholeheartedly appreciate your valued presence and involvement with Guru Nanak Institute of Pharmaceutical Science and Technology.

Prof. (Dr.) Abhijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

It is my great pleasure to extend a warm welcome to you to Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST).

GNIPST is among the leading educational institutes of West Bengal aiming to provide quality pharmacy education to students.

GNIPST was established in 2005, approved by PCI, and affiliated with Maulana Abul Kalam Azad University of Technology, West Bengal. The institute is also the first pharmacy institute in West Bengal to receive accreditation from NAAC and NBA and the only private Pharmacy Autonomous institute in West Bengal. GNIPST is proud to be an NIRF Ranked Pharmacy Institute, being the 74th ranked institute in 2024.

As we celebrate Independence Month, let us also honor the freedom to learn, innovate, and excel in our chosen fields. We sincerely believe that rich values and traditions imbibed here, along with proper educational facilities, would carry the students to greater levels in their life. I believe PHARMACY will be a rewarding profession for you in the future.

Prof. (Dr.) Lopamudra Datta

"The best way to find yourself is to lose yourself in the service of others."

— Mahatma Gandhi



RECENT RESEARCHES

India commits US\$ 85 million to WHO Global Traditional Medicine Centre

[READ MORE](#)

<https://www.who.int/news/item/31-07-2024-india-commits-usd-85-million-to-who-global-traditional-medicine-centre#:~:text=Worldwide%20traditional%20medicine%20is%20used,WHO%20Global%20Traditional%20Medicine%20Centre.>

On World Breastfeeding Week, UNICEF and WHO call for equal access to breastfeeding support”

[READ MORE](#)

<https://www.who.int/news/item/31-07-2024-on-world-breastfeeding-week--unicef-and-who-call-for-equal-access-to-breastfeeding-support>

Worldwide, traditional medicine is used by billions of people for their health and well-being. At a signing ceremony in Geneva, the Government of India committed US\$ 85 million over 10 years, 2022–2032, to support the programming of the WHO Global Traditional Medicine Centre. India’s 10-year financial contribution will support a cross-sectoral program of work to strengthen the evidence base for traditional medicine by providing data and evidence on traditional medicine policies, practice, products, and public use. This support will scale up WHO’s capacities on traditional medicine across technical divisions and regions in the spirit of global collaboration and solidarity. Part of this substantial contribution from the Government of India will also be included in WHO’s Investment Round to resource WHO’s core work during 2025–2028

In the last 12 years, the number of infants under six months of age globally who are exclusively breastfed has increased by more than 10%. This means 48% of infants worldwide now benefit from this healthy start in life. It translates to hundreds of thousands of babies whose lives have been saved by breastfeeding. While this significant leap brings us closer to the World Health Organization target of increasing exclusive breastfeeding to at least 50% by 2025, there are persistent challenges that must be addressed. When mothers receive the support they need to breastfeed their babies, everyone benefits. Improving breastfeeding rates could save over 820 000 children’s lives each year, according to the latest available data.

“Service without humility is selfishness and egotism.”

— Mahatma Gandhi



RECENT RESEARCHES

New initiative launched to advance mRNA vaccine development against human avian influenza (H5N1)

READ MORE

[https://www.who.int/news/item/29-07-2024-new-initiative-launched-to-advance-mrna-vaccine-development-against-human-avian-influenza-\(h5n1\)#:~:text=The%20mRNA%20Technology%20Transfer%20Programme,production%20of%20mRNA%2Dbased%20vaccines.](https://www.who.int/news/item/29-07-2024-new-initiative-launched-to-advance-mrna-vaccine-development-against-human-avian-influenza-(h5n1)#:~:text=The%20mRNA%20Technology%20Transfer%20Programme,production%20of%20mRNA%2Dbased%20vaccines.)

Breakthrough in bid to develop vaccines and drugs for neglected tropical disease

READ MORE

<https://www.sciencedaily.com/releases/2024/08/240802132859.htm>

A new project aiming to accelerate the development and accessibility of human avian influenza (H5N1) messenger RNA (mRNA) vaccine candidates for manufacturers in low- and middle-income countries has been launched today. The Argentinian manufacturer Sinergium Biotech will lead this effort leveraging the World Health Organization (WHO) and the Medicines Patent Pool (MPP) mRNA Technology Transfer Programme. The mRNA Technology Transfer Programme, jointly developed by WHO and MPP, was launched in July 2021 with the aim to build capacity in low- and middle-income countries (LMICs) for the development and production of mRNA-based vaccines. Sinergium Biotech, a partner in the mRNA Technology Transfer Programme, has developed candidate H5N1 vaccines and aims to establish proof-of-concept in preclinical models. Once the preclinical data package is concluded, the technology, materials, and expertise will be shared with other manufacturing partners, aiding the acceleration of the development of H5N1 vaccine candidates, and bolstering pandemic preparedness efforts.

The breakthrough, by a team from the University of York and Hull York Medical School, is described in the journal Nature Medicine and lays the foundations for vaccine development and for testing new preventative measures which lays the foundations for vaccine development and for testing new preventative measures against the neglected tropical disease leishmaniasis.

NEW DRUG APPROVALS

JULY 2024



Kisunla (donanemab-azbt) Injection

- **Company:** Eli Lilly and Company
- **Date of Approval:** July 2, 2024
- **Treatment for:** Alzheimer's Disease

1

2

Epysqli (eculizumab-aagh) Injection

- **Company:** Samsung Bioepis Co., Ltd.
- **Date of Approval:** July 19, 2024
- **Treatment for:** paroxysmal nocturnal hemoglobinuria

3

Femlyv Orally Disintegrating Tablets

- **Company:** Millicent Puerto Rico LLC
- **Date of Approval:** July 22, 2024
- **Treatment for:** Birth Control

4

Leqselvi (deuruxolitinib phosphate) Tablets

- **Company:** Sun Pharmaceutical Industries Inc.
- **Date of Approval:** July 25, 2024
- **Treatment for:** Alopecia Areata

5

benzgalantamine Delayed-Release Tablets - formerly ALPHA-1062

- **Company:** Alpha Cognition Inc.
- **Date of Approval:** July 26, 2024
- **Treatment for:** Alzheimer's Disease

6

(paliperidone palmitate) Extended-Release Injectable Suspension

- **Company:** Luye Pharma Group
- **Date of Approval:** July 26, 2024
- **Treatment for:** Schizophrenia, Schizoaffective Disorder

LEARN

MORE


<https://www.drugs.com/newdrugs.html>



“It's a fight for freedom, freedom with past for the coming future.”

Mangal Pandey

Latest Generic Drug Approvals



INDIUM IN-111 PENTETREOTIDE INJECTION KIT 3 MCI/ML

Approved: July 1, 2024 - Sun Pharmaceutical Industries, Inc.
Used for: Diagnosis and Investigation
Generic for: Octreoscan

1

2

BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION 133 MG/10 ML (13.3 MG/ML) AND 266 MG/20 ML (13.3 MG/ML)

- **Approved:** July 1, 2024 - Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- **Used for:** Analgesia
- **Generic for:** Exparel



3

L-GLUTAMINE POWDER FOR ORAL SOLUTION 5GM/PACKET

- **Approved:** July 8, 2024 - Novitium Pharma LLC
- **Used for:** Sickle Cell Disease
- **Generic for:** Endari



NIMODIPINE ORAL SOLUTION 3 MG/ML

5

4

- **Approved:** July 9, 2024 - Annora Pharma Private Limited
- **Used for:** Subarachnoid Hemorrhage
- **Generic for:** Nymalize



TAZAROTENE TOPICAL CREAM 0.05%

- **Approved:** July 15, 2024 - Padagis Israel Pharmaceuticals Ltd.
- **Used for:** Plaque Psoriasis
- **Generic for:** Tazorac Cream 0.05%

LEARN

MORE

<https://www.drugs.com/newdrugs.html>

DISEASE OUTBREAK NEWS



1. Antimicrobial Resistance, Hypervirulent *Klebsiella pneumoniae* – Global situation 31 July 2024



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON527>

Situation at a glance

In early 2024, the Global Antimicrobial Resistance and Surveillance System on Emerging Antimicrobial Resistance Reporting (GLASS-EAR) issued a request for information to assess the current global situation given the increased identification of isolates of hypervirulent *Klebsiella pneumoniae* (hvKp) sequence type (ST) 23 carrying resistant genes to the carbapenem antibiotics – carbapenemase genes. *K. pneumoniae* strains that can cause severe infections in healthy individuals and have been identified with increasing frequency in recent years are considered hypervirulent compared to classical strains because of their ability to infect both healthy and immunocompromised individuals and because of their increased tendency to produce invasive infections. The presence of hvKp ST23 was reported in at least one country in all six WHO Regions. The emergence of these isolates with resistance to last-line antibiotics like carbapenems necessitates the administration of alternative antimicrobial treatment, which may not be available in many contexts. WHO recommends that Member States progressively increase their laboratory diagnostic capacity to allow for the early and reliable identification of hvKp, as well as reinforce laboratory capacities in molecular testing and detection and analyses of relevant virulence genes in addition to resistance genes. The assessment of risk at the global level is moderate given the challenges with surveillance, lack of information on laboratory testing rates, track and scale of community transmission, the gap in the available data on infections, hospitalization, and the overall burden of the disease.

Dengue – Iran (Islamic Republic of) 22 July 2024



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON526>

Situation at a glance

As of 17 July 2024, the total number of locally acquired (autochthonous) dengue cases in the country has risen to 12, all reported in Bandar-Lengheh. Dengue is a mosquito-borne viral disease caused by the dengue virus, with the potential to cause a serious public health impact. The primary vectors that transmit the disease are mosquitos of the *Aedes* genus, primarily *Aedes aegypti* and, to a lesser extent, *Aedes albopictus*. Iran's MoHME has enacted measures to strengthen hospital readiness. The World Health Organization (WHO) is supporting the MoHME to enhance surveillance, distributing medical and rapid diagnostic supplies, providing training, and organizing risk communication and community engagement (RCCE) activities. On 16 May 2024, WHO reassessed the global risk of dengue as high, reiterating that dengue remains a global public health threat. The risk for Iran is also high due to the presence of the vector in the country, favourable climate conditions for the vector and the movement of people from countries with ongoing dengue outbreaks and endemic areas to Iran.



The Training and Placement Cell of Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) successfully organized an off-campus drive at Torrent Pharmaceutical Ltd (Unit-1) in Sikkim on 7th July 2024 where our total no. of seven students from B.Pharm, Batch-2024 have been placed in various departments, achieving commendable positions with promising career prospects.

Sovan Sarkar (B.Pharm, Batch-2024) were placed in QC Department, Torrent Pharmaceutical Ltd (Unit-1) in Sikkim



Sudipta Deb (B.Pharm, Batch-2024) were in Technology Transfer Department, Torrent Pharmaceutical Ltd (Unit-1) in Sikkim



We are proud to announce that our students Rudradev Mondal, Swapnamoy Samui and Sajidur Rahaman (B.Pharm, Batch-2024) were placed in Production Department, Torrent Pharmaceutical Ltd (Unit-1) in Sikkim

Sayan Mandal and Sahil Akhter Molla (B.Pharm, Batch-2024) were in Packaging Department, Torrent Pharmaceutical Ltd (Unit-1) in Sikkim.

We are proud to announce that our

nirf Rank 2024 is
74

Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) successfully organized a National Seminar (in Hybrid mood) on "Traditional System of Medicine to combat Diabetes and its related Pathological Complication"



The seminar "Made in GNIPST 2024" featured an engaging interaction between alumni and current students, focusing on an idea competition. Alumni shared their career journeys, highlighting how their experiences at GNIPST shaped their professional paths and contributed to their success.



MEDICAL PRACTITIONERS AS FREEDOM FIGHTERS

Where Scientific Pursuits Converge with the Fight for Independence.



Dr. Dattatreya Vinayak Patwardhan

Patwardhan was a lawyer as well as a doctor. During the annual religious festival at Limb in Satara on April 8, 1933, Dr. Patwardhan performed kirtan to inspire people to muster unity for the cause of independence. He was prosecuted for this act, but he remained committed to the cause of Indian independence and continued to work toward it in his way. On August 21, 1934, Dr. Patwardhan performed kirtan at Bavdan in Wai, where he touched on political subjects. He was a dedicated freedom fighter who actively participated in the Indian independence movement. He was involved in various anti-colonial activities and supported the Congress Party's efforts for self-rule. His contributions were notable in the struggle for India's freedom through both political and social reforms.

She was an Indian physician, a lifelong follower of Mahatma Gandhi, and a politician. In 1952 she entered politics and was elected to the Legislative Assembly of Delhi. From 1952 to 1955 she served as Health Minister in Nehru's cabinet. She was Speaker of the Delhi Vidhan Sabha (as the State Assembly had been renamed) from 1955 to 1956. In 1957, she was elected to the Lok Sabha, from Jhansi Constituency, and served till 1971. She was Union Health Minister again from 1962 to 1967. During the congress regime, she fell out with Indira Gandhi and joined (Janata party). She was elected to Lok Sabha from Jhansi in 1977 when her new party was voted to power that created history by overthrowing Indira Gandhi's government. Thereafter she retired from politics to devote herself to the Gandhian ideal. She had set up the Mahatma Gandhi Institute of Medical Sciences in 1969, and remained committed to confine her energies to developing and extending it.



Sushila Nayyar

Syed Mohammad Sharfuddin Quadri (25 December 1901 – 30 December 2015) was an Indian independence activist, Gandhian and a physician of the Unani system of medicine. He was a notable figure in the Indian freedom struggle, particularly active during the late 19th and early 20th centuries. He was deeply involved in the political and social reform movements aiming to challenge colonial rule. Quadri worked alongside other prominent leaders to promote nationalism and fight against British imperialism. His efforts included organizing protests and advocating for greater Indian representation and rights. Through his activism, he contributed significantly to the broader struggle for India's independence.



Syed Mohammad Sharfuddin Quadri



Game Time


Crossword PH-2

ACROSS

2. The city in which Sabarmati Ashram is located
4. India got its independence in this month
11. India's National Anthem was originally written in this language
12. The first prime Minister of India
13. The fabric that was made popular by Gandhi
14. Birthplace of Mahatma Gandhi
15. He composed India's National Anthem

DOWN

1. The first two letters of India's National Anthem
3. Gandhi's father's name
5. Indian Flag is commonly known by this name in Hindi
6. India gained independence from this country
7. The wheel in the Indian Flag is known by this name
8. The Sanskrit term that was used by Gandhi for 'non-violence'
9. Wife of Gandhi
10. Another name for 'People of God' that was popularized by Gandhi



Do you know???



- She was imprisoned for activism during India's struggle for independence.
- She was Indian ambassador in Moscow, Washington and Mexico, the leader of the Indian UN delegation (1946-48, 1952-53)
- The wife of Ranjit Sitaram Pandit who died in jail after being arrested for Independence activism.

Stay tuned for the next edition for a shout out to fastest correct answers!

Submit your answer




or





Game Time

Answer for Crossword PH-1



Cheers to the Victor!

Volume -1, Issue -1



Banisha Mitra

B.Pharm, 3rd Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Editorial Board

Editor-in-Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com